Antiemetic Drugs: Classification, Mechanism & GPAT Notes

Introduction to Antiemetic Drugs

Nausea and vomiting are protective physiological reflexes designed to rid the gastrointestinal tract of toxic substances. However, excessive or prolonged vomiting leads to dehydration, electrolyte imbalances, and metabolic alkalosis. Antiemetic drugs are pharmacological agents used to prevent or suppress nausea and vomiting.

For competitive pharmacy exams like GPAT and NIPER, antiemetics are among the most frequently tested topics in gastrointestinal pharmacology. Understanding their receptor targets, anatomical sites of action, and specific clinical uses is essential for scoring well.

---

Physiology of the Vomiting Centre

Vomiting is coordinated by the vomiting centre (VC) located in the medulla oblongata. The vomiting centre receives input from four primary pathways:

1. Chemoreceptor Trigger Zone (CTZ): Located in the area postrema on the floor of the fourth ventricle. Crucially, the CTZ lies outside the blood-brain barrier (BBB). It detects circulating toxins, drugs (such as cisplatin), and metabolic by-products.
2. Vestibular Apparatus: Detects motion and body position. Relays signals via the vestibulocochlear nerve to the cerebellum and vomiting centre.
3. Gastrointestinal Tract (Visceral Afferents): Vagal and sympathetic afferent nerves detect gut irritation, mechanical distention, and mucosal injury.
4. Higher Cortical Centres: Mediate nausea triggered by sensory stimuli, fear, anxiety, or anticipatory responses.

Key neurotransmitters involved in these emetic circuits include dopamine ($D_2$), serotonin ($5-HT_3$), histamine ($H_1$), acetylcholine (Muscarinic, $M_1$), and substance P (Neurokinin-1, $NK_1$).

---

Classification of Antiemetic Drugs

Antiemetic drugs are classified based on the primary receptor system they block:

1. 5-$HT_3$ Receptor Antagonists (Serotonin Blockers)

• Examples: Ondansetron, Granisetron, Tropisetron, Palonosetron.
• Mechanism: Selectively block peripheral 5-$HT_3$ receptors on vagal afferents in the gut and central 5-$HT_3$ receptors in the CTZ.
• Clinical Uses: First-line therapy for Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Postoperative Nausea and Vomiting (PONV).

2. Dopamine ($D_2$) Receptor Antagonists

• Phenothiazines: Prochlorperazine, Promethazine, Chlorpromazine.
• Butyrophenones: Haloperidol, Droperidol.
• Substituted Benzamides (Prokinetics): Metoclopramide, Domperidone.
• Mechanism: Inhibit $D_2$ receptors in the CTZ and enhance upper GI motility (prokinetic action).

3. Neurokinin-1 ($NK_1$) Receptor Antagonists

• Examples: Aprepitant, Fosaprepitant, Rolapitant, Netupitant.
• Mechanism: Selectively cross the blood-brain barrier to block substance P from binding to central $NK_1$ receptors in the vomiting centre and CTZ.
• Clinical Uses: Highly effective for delayed emesis associated with cisplatin and other emetogenic chemotherapy regimens.

4. $H_1$ Antihistamines

• Examples: Dimenhydrinate, Diphenhydramine, Promethazine, Cinnarizine, Meclizine, Doxylamine.
• Mechanism: Block $H_1$ receptors and associated central muscarinic receptors in the vestibular pathway.
• Clinical Uses: Motion sickness, vertigo (Ménière's disease), and morning sickness in pregnancy (Doxylamine + Pyridoxine).

5. Anticholinergic (Antimuscarinic) Drugs

• Example: Hyoscine (Scopolamine).
• Mechanism: Blocks muscarinic $M_1$ receptors in the vestibular nuclei and the vomiting centre.
• Clinical Uses: Drug of choice for the prevention of motion sickness (administered transdermally).

6. Adjuvant and Miscellaneous Antiemetics

• Corticosteroids: Dexamethasone, Methylprednisolone (synergistic with 5-$HT_3$ blockers in CINV).
• Cannabinoids: Dronabinol, Nabilone ($CB_1$ receptor agonists used for refractory CINV).

---

Antiemetic Drug Comparison Table

Drug Class	Prototype Drug	Major Mechanism	Key Clinical Indication	Frequent Adverse Effects
5-$HT_3$ Antagonist	Ondansetron	Blocks 5-$HT_3$ in gut & CTZ	Acute CINV, PONV	Headache, constipation, QT prolongation
$D_2$ Antagonist (Prokinetic)	Metoclopramide	Central $D_2$ block + 5-$HT_4$ agonism	Diabetic gastroparesis, GERD, emesis	Extrapyramidal symptoms, hyperprolactinemia
$D_2$ Antagonist (Peripheral)	Domperidone	Peripheral $D_2$ blocker (does not cross BBB)	Drug-induced emesis, non-ulcer dyspepsia	Cardiac arrhythmias (QT prolongation), galactorrhea
$NK_1$ Antagonist	Aprepitant	Blocks substance P at central $NK_1$	Delayed phase CINV	Fatigue, hiccups, CYP3A4 interactions
Antimuscarinic	Hyoscine	Blocks $M_1$ in vestibular nuclei	Motion sickness prophylaxis	Dry mouth, blurred vision, urinary retention
$H_1$ Blocker	Doxylamine	Central $H_1$ and $M_1$ blockade	Hyperemesis gravidarum (with Vitamin B6)	Sedation, drowsiness

---

High-Yield Pharmacology Concepts for GPAT

Metoclopramide vs. Domperidone

• Metoclopramide crosses the blood-brain barrier readily. It produces central $D_2$ blockade, causing extrapyramidal symptoms (EPS) like acute dystonia and akathisia, especially in children and young adults.
• Domperidone does not readily cross the blood-brain barrier. It works on the CTZ (which is outside the BBB) without blocking basal ganglia $D_2$ receptors, making it virtually free of extrapyramidal side effects.

Acute vs. Delayed CINV

• Acute phase (first 24 hours): Primarily driven by peripheral serotonin release from enterochromaffin cells. Ondansetron + Dexamethasone is the treatment regimen of choice.
• Delayed phase (days 2 to 5): Driven by substance P acting on $NK_1$ receptors. Aprepitant + Dexamethasone is the combination of choice.

Second-Generation 5-$HT_3$ Antagonist: Palonosetron

• Palonosetron possesses a distinct chemical structure with a significantly longer half-life (~40 hours) compared to Ondansetron (~4 hours).
• It exhibits allosteric cooperativity and receptor internalization, making it the only 5-$HT_3$ blocker approved for both acute and delayed CINV prevention.

---

Summary Points for Rapid Revision

• The CTZ is located in the area postrema outside the blood-brain barrier.
• Hyoscine is the most effective drug for the prevention of motion sickness.
• Doxylamine combined with Pyridoxine (Vitamin B6) is the first-line pharmacotherapy for morning sickness in pregnant patients.
• Ondansetron does not alter gastrointestinal motility, avoiding the diarrhea or cramping seen with prokinetic agents.
• Extrapyramidal side effects of metoclopramide can be treated using centrally acting anticholinergics like trihexyphenidyl or antihistamines like diphenhydramine.